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The molecular mechanisms underlying the neuronal signaling changes in alcohol
addiction and withdrawal are complex and multifaceted. The cortico-striatal circuit
is highly implicated in these processes, and the striatum plays a significant role
not only in the early stages of addiction, but in the developed-addictive state as
well, including withdrawal symptoms. Transcriptional analysis is a useful method for
determining changes in gene expression, however, the results do not always accurately
correlate with protein levels. In this study, we employ label-free proteomic analysis to
determine changes in protein expression within the striatum during chronic ethanol use
and early withdrawal. The striatum, composed primarily of medium spiny GABAergic
neurons, glutamatergic and dopaminergic nerve terminals and astrocytes, is relatively
homogeneous for proteomic analysis. We were able to analyze more than 5000
proteins from both the dorsal (caudate and putamen) and ventral (nucleus accumbens)
striatum and identified significant changes following chronic intermittent ethanol exposure
and acute (8 h) withdrawal compared to ethanol naïve and ethanol exposure groups
respectively. Our results showed significant changes in proteins involved in glutamate
and opioid peptide signaling, and also uncovered novel pathways includingmitochondrial
function and lipid/cholesterol metabolism, as revealed by changes in electron transport
chain proteins and RXR activation pathways. These results will be useful in the
development of novel treatments for alcohol withdrawal and thereby aid in recovery from
alcohol use disorder.
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INTRODUCTION
The cortico-striatal circuit is highly implicated in both substance addiction and withdrawal. The
different regions of this circuit are being intensely studied and extensive gene expression analyses
have been performed (Bell et al., 2006; Melendez et al., 2012; Osterndorff-Kahanek et al., 2013,
2015; Most et al., 2015), effectively informing future research directions to aid in the development
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of potential therapeutics. However, gene expression does not
always correlate with protein levels, especially during acute
homeostatic changes, such as those occurring during early
withdrawal. In fact, previous work has demonstrated that rapid
modulation of synaptic protein expression may occur primarily
via local translation of dendritic and axonal mRNA (Aguilar-
Valles et al., 2015; Hussain and Bashir, 2015). Furthermore,
ethanol may directly affect the activity or degradation of
numerous proteins due to its lipophilic interaction with the
plasma membrane and lipid rafts (Collin et al., 2014; Tang
et al., 2014; Huang et al., 2016). The complexity of neuronal
circuits involved in addiction and the multiphasic nature of
addiction and withdrawal make it likely that changes in protein
levels and/or function during addiction are both spatially and
temporally dependent. Therefore, we performed a total protein
analysis using label-free proteomics on the entire striatum of
C57BL/6J mice undergoing chronic intermittent ethanol (CIE)
exposure or acute withdrawal. This quantitative method of
measuring protein levels provides a comprehensive and accurate
depiction of real-time molecular events without relying on
substrate labeling procedures. By comparing this systematic
analysis of protein expression to previous transcriptional studies,
the underlying mechanisms behind dysfunctional signaling in
multiple regions of the striatum during various phases of
addiction and withdrawal may be more accurately determined.
Research into the neuronal mechanisms of addiction has
revealed changes primarily in the dopamine (DA), gamma-
aminobutyric acid (GABA) and glutamate signaling pathways
(Koob and Volkow, 2010; Koob, 2014; Most et al., 2014; Wang
et al., 2014, 2015; Volkow et al., 2015; Didone et al., 2016).
These changes are induced not only by the substance of abuse,
but also by the context of conditioning (learning and memory),
resulting in complex and variable neuroplastic changes occurring
both dependently and independently of the substance of abuse
(Berke and Hyman, 2000; Cunningham et al., 2006; Lobo and
Nestler, 2011; Nam et al., 2013). One way of minimizing neuronal
effects of the contextual and behavioral components of addiction
in order to focus on the direct effects of alcohol is through
passive ethanol exposure. Accordingly, the CIE procedure has
been shown to reliably generate alcohol dependence in animals
(Becker and Lopez, 2004; Lopez and Becker, 2005; DePoy
et al., 2013; Meinhardt and Sommer, 2015) and produce severe
withdrawal symptoms including ethanol withdrawal seizures,
which peak 8 h after ethanol removal in mice as previously
reported (Becker et al., 1997; Kim et al., 2011; Maldonado-
Devincci et al., 2014; Meinhardt and Sommer, 2015), making
it a powerful method for studying neuronal signaling during
withdrawal.
It has been shown that alcohol dependence is caused by
neuroadaptation to prolonged and excessive consumption of
alcohol, a CNS depressant (Tsai et al., 1998). This dependence can
lead to severe withdrawal symptoms upon cessation of alcohol
consumption, termed alcohol withdrawal syndrome (AWS).
AWS, which manifests with symptoms ranging from nausea
and insomnia to hallucinations and seizures, may result in
death due to severe symptoms associated with status epilepticus
during the first 24 h of withdrawal in people (Bayard et al.,
2004; Campos et al., 2011). These symptoms appear to result
from increased neuronal excitability as a consequence of reduced
GABA activity (Crews et al., 2013) and increased glutamatergic
neurotransmission (Tsai et al., 1998). AWS is not only a medical
emergency, but early symptoms can produce extreme discomfort
increasing the drive to drink and impeding successful recovery
from alcohol use disorder (AUD). Therefore, the development of
therapeutics aimed at reducing or eliminating AWS is crucial for
effective recovery from AUD.
The molecular mechanisms underlying the maladaptive
neuronal signaling found in AUD and AWS are multifaceted, and
remain undetermined. The dorsal (caudate and putamen, CPu)
and ventral (nucleus accumbens, NAc) striatum play significant
roles not only during early phases of addiction, but also in the
post-addictive state (Chen et al., 2011), contributing to relapse
and withdrawal (Cuzon Carlson et al., 2011). The CPu is a fairly
homogenous region of the corticostriatal circuitry, composed
primarily of medium spiny GABAergic neurons, glutamatergic
nerve terminals, and astrocytes, making it a good candidate for
such an expansive proteomic analysis technique. In contrast, the
NAc is highly involved in motivational and contextual learning
as well as the integration of environmental stimuli, and is more
cellularly heterogeneous, yielding a less unified and perhapsmore
variable analysis (Koob and Volkow, 2010; Lobo and Nestler,
2011; Hinton et al., 2014). The results of proteomic changes in
both regions are reported here for a comprehensive analysis of
the effects of CIE exposure and acute withdrawal on the protein
levels in the entire striatum.
MATERIALS AND METHODS
Animals
Male C57BL/6J mice (6 weeks old, Jackson Laboratories, Bar
Harbor, ME) were grouped housed in standard Plexiglas cages
under a 12 h light/dark cycle with lights on at 6:00 a.m. Food
and water were provided ad libitum. Animal care and handling
procedures were approved by the Mayo Clinic Institutional
Animal Care and Use Committee (IACUC) in accordance with
National Institutes of Health guidelines. At 8 weeks of age mice
were randomly assigned to either ethanol or saline/air control
groups. One cohort was used for proteomic analyses (n = 4–5
mice per group), while a separate cohort was used for behavioral
testing (n = 9–10 mice per group).
Chronic Intermittent Ethanol
Administration
The CIE paradigm has been described in detail elsewhere (Becker
and Lopez, 2004). Briefly, mice were exposed to ethanol vapor or
room air using vapor administration chambers (La Jolla Alcohol
Research, Inc., La Jolla, CA) for 16 h during the dark phase,
followed by 8 h of room air in their home cages during the light
phase. This process was repeated for 4 consecutive days, followed
by 3 days in their home cages with room air (withdrawal period).
This 7-day procedure entails one CIE cycle. We chose to use four
CIE cycles (Figure 1A), as it has been shown to increase handling
induced seizures and ethanol consumption in mice (Metten et al.,
2010; DePoy et al., 2013). Ethanol was vaporized by pumping
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FIGURE 1 | Flow-chart of the experimental steps for proteomic analysis. The CIE protocol and tissue harvest time points are depicted (A). Tissue dissection
(caudate and putamen shown for demonstration), protein extraction and subsequent proteomic analysis steps are shown (B), followed by bioinformatics and protein
identification steps (C).
95% ethanol into a heated flask to mix the vaporized ethanol with
room air, continuously pumping the mixture into the chambers
to maintain a concentration of 3.0–5.0mg ethanol/liter of air.
Air control chambers received identical airflow rates from room
air. Prior to each vapor exposure, mice undergoing ethanol
treatment were administered 1.5 g/kg ethanol (20% v/v in 0.9%
saline) and 68.1mg/kg pyrazole (SigmaAldrich, St. Louis, MO)
in a single intraperitoneal (i.p.) injection to help initiate ethanol
intoxication and maintain stable blood ethanol concentrations
(BACs), respectively (Becker et al., 1997). Saline/air control mice
received equal volume i.p. injections of 68.1mg/kg pyrazole
dissolved in 0.9% saline. After injections, mice were immediately
placed inside the vapor chambers with food and water ad libitum.
These procedures yielded consistent BACs of approximately 200
mg/dL for the duration of the CIE procedure.
Blood Alcohol Concentration Analysis
Mouse blood (∼30µL) was collected from tail veins with
heparinized capillary tubes during the final hour of the fourth
ethanol treatment each week for BAC analysis. Plasma BAC was
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determined using the Analox AM1 system (Analox Instruments
USA, Lunenburg,MA). Statistical significance was determined by
one-way ANOVA (for overall group BACs) or two-way ANOVA
(for individual BACs) followed by Tukey post-hoc analysis for
multiple comparisons.
Ethanol Drinking
Mice were tested for preference and consumption of 10% ethanol
before and after CIE using the two-bottle continuous access,
free-choice drinking test. Before CIE exposure, mice were given
unlimited access to two bottles for 8 days. For the first 4 days,
both bottles contained tap water to train the animals and to
establish overall fluid consumptions. For the last 4 days, one
bottle contained 10% ethanol and the other contained tap water.
Initially and every 2 days thereafter at the same time of day, mice
and bottles were weighed, and bottle positions were alternated to
control for side preference.
After CIE, ethanol drinking was tested again for 14 days. Mice
were individually housed for the duration of the drinking tests
with ad libitum access to food. Data were analyzed by two-way
repeated measures ANOVA with Bonferroni post-hoc tests.
Loss of Righting Reflex
Fourteen days after the end of the final CIE cycle, mice were
tested for loss of righting reflex (LORR). Mice were injected
with a high dose of ethanol (i.p., 3.6 gm/kg; 20% (v/v) mixed
in isotonic saline), and were intermittently placed on their backs
in a v-shaped trough until they lost the ability to return to an
upright position on all four paws. Time to recovery of LORR was
measured and operationally defined as the length of time from
initial LORR to when the mouse could right itself onto all four
paws three times within a 30 s interval. Data were analyzed by
unpaired two-tailed Student t-tests.
Tissue Collection and Protein Extraction
Mice receiving ethanol treatments were randomly divided into
chronic ethanol (E) and early withdrawal (W) groups. E and
saline/air (C) control mice were sacrificed at the end of the
final 16 h of vapor exposure for tissue collection. W mice were
removed from the vapor chambers at the same time point and
blood was immediately collected for BAC analysis. W mice
remained in their home cages in room air for 8 h before being
sacrificed for tissue collection (Figure 1A).
Mice were anesthetized using carbon dioxide and the brains
were immediately removed and washed in ice-cold PBS. Trunk
blood was collected concurrently using heparinized capillary
tubes for BAC analysis. The dorsal striatum was dissected from
both hemispheres and immediately frozen on dry ice. To extract
total protein, 0.5mm zirconium oxide beads and 50µL of ice-
cold lysis buffer [CelLytic MT lysis reagent (Sigma-Aldrich),
complete protease inhibitor cocktail (Roberts, Roche et al.) and
phosphatase inhibitor cocktails type 2 and 3 (Sigma-Aldrich)]
were added to the tissues. Tissues were homogenized in a Storm
24 Bullet Blender (Next Advance Inc, Averill Park NY, USA)
for 4min at 4◦C and speed 4. Homogenates were centrifuged
at 16,400 rpm at 4◦C for 15min. Supernatants were collected
and analyzed for protein concentrations using Bradford Reagent
(Bio-Rad). Equal amounts of protein from each animal for
each group (n = 4) were pooled for subsequent denaturing
electrophoresis (SDS-PAGE) (Figure 1B).
Protein Preparation for LC-MS/MS
Protein concentrations of the pooled protein samples were
confirmed, and equal amounts of protein were denatured by
boiling in NuPAGE R©LDS Sample Buffer (Invitrogen, Carlsbad,
CA) for 10min at 70◦C. Denatured lysates were loaded in
triplicate (15µg per lane) and resolved on a 4–12% Bis-Tris
Gel (Figure 1B) in MOPS running buffer (Invitrogen, Carlsbad,
CA). Gels were fixed with 50% methanol in 10% acetic acid,
washed in ultra-pure water, then stained with Bio-Safe Coomassie
Stain (Bio-Rad, Hercules, CA) per manufacturer’s instructions.
Gel lanes were then divided into 5 evenly spaced horizontal
regions using protein bands that were common to all samples as
guides. The middle half of each sample lane was cut length-wise.
Gel sections were digested with trypsin following a previously
described protocol (Hogan et al., 2015). In brief, each gel section
was de-stained, reduced with dithiothreitol and alkylated with
iodoacetamide. Proteins were digested overnight at 37◦C with
140 ng of trypsin dissolved in 25mMTris (pH 8.2). Peptides were
extracted from the gel piece with 50% acetonitrile (ACN) in 4%
trifluoroacetic acid (TFA), followed by two additional extractions
with ACN. The combined extracts were evaporated to dryness
on a vacuum concentrator and stored at −80◦C until further
analysis.
Liquid Chromatography-Tandem Mass
Spectrometry (LC-MS/MS) Analysis
Peptide extract from each gel section (see Figure 1B) was
reconstituted in 40µL HPLC-grade water containing 0.2%
formic acid (FA), 0.1% TFA, and 0.002% Zwittergent 3–16.
10µL of the peptide extract (15µL for the two higher molecular
weight gel sections) were loaded onto a 0.25µL bed OptiPak
trap (Optimize Technologies, Oregon City, Oregon) custom-
packed with 5µm, 200Å Magic C8 (Bruker-Michrom, Auburn,
CA) stationary phase. Loaded trap was washed for 4min with
an aqueous loading buffer of 0.2% FA and 0.05% TFA at
10µL /min. Following the wash, peptides were transferred
via 10-port valve onto a 35 cm × 100µm PicoFrit column
9 (NewObjective, Woburn, MA), self-packed with Agilent
Poroshell 120S 2.7µm EC-C18 stationary phase, using a Dionex
UltiMate R© 3000 RSLC liquid chromatography (Ferrer-Alcón
et al., 2003) system (Thermo-Fisher Scientific, Waltham, MA).
Peptides were separated using a 400 nL/min LC gradient
comprised of 2–30%B in 0–70min, 30–50%B from 70 to 100min,
50–95%B from 100 to 104min, held at 95%B for 8min and re-
equilibrated to 2%B. Mobile phase A was 2% ACN in water
with 0.2% FA and mobile phase B was ACN/isopropanol/water
(80/10/10 by volume) with 0.2% FA. Eluting peptides were
analyzed using a QExactive mass spectrometer (Thermo-Fisher
Scientific, Waltham, MA). The instrument was operated in data-
dependent mode by collecting MS1 data at 70,000 resolving
power (measured at m/z 200) with an AGC value of 3E6 over
an m/z range of 350–2000, using lock masses from background
polysiloxanes at m/z 371.10123 and 445.12002. Precursors were
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fragmented with normalized collision energy of 27, fragments
measured at 17,500 resolving power and a fixed first mass of
140. Tandem mass spectra (MS/MS) were collected on the top
15 precursor masses present in each MS1 using an AGC value
of 1E5, max ion fill time of 100ms, an isolation window of 3.0
Da, isolation offset of 0.5 Da, and a dynamic exclusion time
of 60s.
Bioinformatic Analysis of LC-MS/MS Data
We utilized a label-free peptide MS1 intensity-based method for
finding differentially expressed proteins between experimental
groups (Figure 1C). The quality of the raw data was assessed
using the quality control metrics in the Swift proteomic
data processing pipeline (Zenka et al., 2011). MaxQuant
(version 1.5.1) software processed the raw data files to
produce a list of protein groups and their corresponding
intensities in each sample (Cox et al., 2014). To accomplish
this, MaxQuant was configured to use a composite mouse
protein sequence database containing UniProt mouse reference
proteome (downloaded on 12 February 2015) and sequences
of common contaminants (trypsin, keratin, cotton, wool, etc.).
Reversed protein sequences were appended to the database for
estimating protein identification false discovery rates (FDRs).
The software was configured to use 20 ppm m/z tolerance for
precursors and fragments while performing peptide-spectrum
matching. The software derived semitryptic peptides from the
sequence database while looking for the following variable
modifications: carbamidomethylation of cysteine (+57.023 Da.),
oxidation of methionine (+15.994 Da.), formation of n-terminal
pyroglutamic acid (−17.023 Da.) and protein n-terminal
acetylation (+42.01 Da.). MaxQuant was instructed to align
the runs and match features between multiple sample runs of
the same gel region. The software filtered peptide and protein
identifications at 2% FDR, grouped protein identifications into
groups and reported protein group intensities.
An in-house script written in R programming language
performed differential expression analysis using protein group
intensities. First, protein group intensities of each sample
were log2 transformed and normalized using Quantile method.
For each protein group, the normalized intensities observed
in two groups of samples were modeled using a Gaussian-
linked generalized linear model. An ANOVA test was used to
detect the differentially expressed protein groups between pairs
of experimental groups. Differential expression p-values were
FDR corrected using Benjamini-Hochberg-Yekutieli procedure.
Protein groups with an FDR < 0.05 and an absolute log2
fold change of at least 0.5 were considered as significantly
differentially expressed and saved for pathway analysis.
FIGURE 2 | Blood alcohol concentrations and behavior tests demonstrate animals display alcohol-dependent phenotype. The blood alcohol
concentrations (BAC) of the mice are within the optimal range for developing alcohol dependence throughout the experiment (A) and during each cycle (B). 10%
ethanol consumption (C) is significantly higher in E mice after CIE treatments (***p < 0.001). CIE mice also demonstrate shorter time to recovery during loss of righting
reflex (LORR) test (D, *p < 0.05).
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Proteomic Data Analysis using Ingenuity
Pathway Analysis Software
QIAGEN’s Ingenuity R© Pathway Analysis (IPA R©, QIAGEN
Redwood City, CA, USA; www.qiagen.com/ingenuity) was used
to analyze the proteins identified as significantly different by the
bioinformatics described above. Proteins were further restricted
to include only those with intensity value readings from all
three technical replicates. The normalized ratios, p-values and
FDRs from these resulting proteins were uploaded to IPA with
their corresponding SwissProt/UniProt identifiers. IPA was then
instructed to only analyze proteins with equal to or greater than
a log2 fold change of 1.25, corrected p-value of less than 0.05, and
a FDR (q-value) of 0.001. IPA Knowledge Base was restricted to
select tissues and cells primarily from the nervous and immune
systems (see Supplemental Data sheet 1 for CPu, and Data
sheet 8 for NAc for IPA settings). IPA used the right tailed
Fisher’s exact test to determine statistical significance. Results
are given with significance (p-value), ratio ([number of proteins
from data set]/[total known proteins in pathway]), and/or z-score
(number of standard deviations above or below the mean) when
applicable.
RESULTS
BAC and Ethanol Consumption
All mice receiving ethanol treatments had the same BAC of
approximately 200 mg/dL for the duration of the CIE procedure,
and at the time of tissue harvest W mice BACs were no different
than C mice (Figures 2A,B. n = 4–5 per group). After the CIE
procedure, mice exposed to ethanol consumed significantly more
10% ethanol during two-bottle choice thanmice exposed to room
air (Figure 2C. n = 9–10 per group, ∗∗∗p < 0.001). These mice
also had a faster time to recovery from loss of righting reflex than
the air control group (Figure 2D. n = 9–10 per group, ∗p< 0.05).
Label-Free Proteomic Analysis
LC-MS/MS analysis (Figures 1B,C) detected between 5085 and
5944 unique proteins from each comparison between the three
treatment groups (CPu: E vs. C = 5085; W vs. E = 5086; W vs.
C= 5086; NAc: E vs. C= 5940; W vs. E= 5944; W vs. C= 5942).
After exclusion of non-triplicate values, up to 5672 proteins from
each comparison were uploaded to IPA for differential expression
analysis (CPu: E vs. C = 4896; W vs. E = 4895; W vs. C = 4893;
NAc: E vs. C = 5648; W vs. E = 5672; W vs. C = 5651). IPA
determined that up to 284 proteins were significantly altered in
each of the three comparisons (CPu: E vs. C = 168; W vs. E =
157; W vs. C = 284; NAc: E vs. C = 148; W vs. E = 231; W vs.
C= 118) under the more restrictive exclusion criteria. (Complete
data sets can be found in Supplemental Materials. CPu data for E
vs. C in Data sheet 2, W vs. E in Data sheet 3, andW vs. C in Data
sheet 4. NAc data for E vs. C in Data sheet 5,W vs. E in Data sheet
6, and W vs. C in Data sheet 7).
From this point forward, this manuscript will focus on the E
vs. C (“E” mice) and W vs. E (“W” mice) groups in an effort to
remain focused on pathways of pre-clinical importance.
FIGURE 3 | Select top significant canonical pathways. Ten of the top
canonical pathways as determined by p-value of overlap between pathway
molecules and our data sets are shown for both (A) ethanol (E vs. C group)
and (B) withdrawal (W vs. E group) in the caudate-putamen (“CPu”) and
nucleus accumbens (“NAc”). Blue indicates negative, and red indicates
positive overall z-scores; gray indicates that a pattern could not be
determined. Complete data can be found in Supplemental Materials.
Top Affected Canonical Pathways
IPA identified hundreds of canonical pathways as significantly
affected in each experimental comparison. The top 10 canonical
pathways, as ranked by p-value, are shown in Figure 3. When
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considering z-scores, an overall trend of decreased activity in the
E mice, and increased activity in W mice is evident for the CPu
data. Following this trend, many pathways were differentially
activated in both striatal regions between the two treatment
groups. In the CPu, for example synaptic plasticity was highly
significantly and differentially altered. In E mice, long-term
potentiation (LTP) was the most significantly affected canonical
pathway, with a relatively large decrease (Figure 3A, z-score= −
1.633) in overall activity, while in W mice activity was slightly
increased (Figure 3B, z-score = 0.82). Long-term depression
(LTD), on the other hand, was significantly increased in W mice
(Figure 3B, z-score = 1.34), but activity change was far less
significant in E mice (p = 0.07) and direction of change could
not be determined. In contrast, eIF2 signaling, which is related
to mRNA translation, was differentially activated in the opposite
direction in the NAc, being increased in E mice (Figure 3A, z-
score= 2.83) but decreased in Wmice (Figure 3B, z-score= −
4), and with far greater significance than any of the pathways in
the CPu (E p-value= 7.76E-10; W p-value= 1.26E-16).
In the CPu, cAMP response element binding protein (CREB)-
related and PKA signaling pathways were among the top affected
canonical pathways. In E mice, activity in these pathways was
decreased (Figure 3A, z-scores for PKA = −1, dopamine-
DARPP32 feedback in cAMP = −2.646, CREB signaling in
neurons = −1.633), while W mice showed increased activity
in dopamine-DARPP32 feedback in cAMP (z-score = 1.00) and
CREB signaling in neurons (Figure 3B, z-score= 0.71), being the
most significantly affected canonical pathway in W mice (p =
1.35E-05). CREB signaling in neurons was also increased in the
NAc during withdrawal (z-score = 1), but was not significantly
altered in the NAc in E mice.
Glutamate receptor signaling was the second most
significantly affected canonical pathway in the CPu of W
mice (Figure 3B, p = 1.62E-05), sharing many of the same
altered proteins as the top 7 affected pathways. In the NAc
oxidative phosphorylation (Figure 3B, p = 1.26E-22) was the
most significantly affected canonical pathway during withdrawal.
Additionally, mitochondrial dysfunction was one of the top 20
significantly affected canonical pathways in W mice (p-values
CPu= 1.02E-02, NAc = 1.00E-19; Figure 3B). Other significantly
activated pathways in the CPu of W mice include FXR/RXR
activation (p = 8.78E-03) and positive acute phase response
proteins (p =1.39E-02; see Supplemental Data sheet 3), reflecting
alterations in lipid metabolism and inflammatory response.
Top Altered Proteins and Upstream
Regulators
Based on our neuroproteomic examination and subsequent
bioinformatic analysis, we were able to identify several key
focus proteins that inherently had the greatest fold change
expression in each comparison group. The top differentially
expressed proteins found in the CPu and NAc are listed in
Tables 1–4, respectively. Though many of the altered proteins
in E mice were related to small molecule biochemistry and
extracellular signaling, the more familiar addiction-associated
proteins were seen in the withdrawal groups (Tables 2, 4), such
as prodynorphin (PDYN), cannabinoid receptor 1 (CNR1) and
calcium/calmodulin-dependent protein kinase IIα (CAMK2A).
TABLE 1 | Select top significantly altered analysis-ready molecules in the caudate-putamen of mice receiving chronic ethanol treatment (relative to
control mice).
Direction of change Protein ID Protein name Accession number Log2 Fold change
UP TRIM32 Tripartite motif containing 32; E3 ubiquitin ligase Q8CH72 4.34E+10
TLE4 Transducin-like enhancer of split 4 Q62441 1.03E+10
LIAS Lipoic acid synthetase Q99M04 6.968
SERPINC1 Serpin peptidase inhibitor, clade C (antithrombin), member 1 P32261 5.965
GPX3 Glutathione peroxidase 3 P46412 4.745
TTR Transthyretin P07309 4.582
MICALL1 MICAL-like 1 Q8BGT6 4.460
CX3CL1 Chemokine (C-X3-C motif) ligand 1 O35188 3.020
TP53I11 Tumor protein p53 inducible protein 11 Q4QQM4 2.898
SERPINF2 Serpin peptidase inhibitor, clade F (alpha−2 antiplasmin,
pigment epithelium derived factor), member 2
Q61247 2.839
DOWN BID BH3 interacting domain death agonist P70444 −7.634
HAP1 Huntingtin-associated protein 1 O35668−2 −5.385
HP Haptoglobin Q61646 −3.997
PTPDC1 Protein tyrosine phosphatase domain containing 1 Q6NZK8−2 −3.799
PLXNC1 Plexin C1 Q9QZC2 −3.310
MYO1B Myosin IB P46735−2 −3.130
AKAP2 A kinase (PRKA) anchor protein 2 O54931-5 −2.939
RGS14 Regulator of G-protein signaling 14 P97492 −2.647
WFS1 Wolfram syndrome 1 (wolframin) P56695 −2.482
DOCK10 Dedicator of cytokinesis 10 Q8BZN6 −2.353
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TABLE 2 | Select top significantly altered analysis-ready molecules in the caudate-putamen of mice during acute withdrawal from chronic ethanol
(relative to mice receiving chronic ethanol).
Direction of change Protein ID Protein name Accession number Log2 Fold change
UP PDYN Prodynorphin O35417 8.682
BID BH3 interacting domain death agonist P70444 8.642
TMSB10 Thymosin beta 10 P62329 4.609
CNR1 Cannabinoid receptor 1 (brain) P47746 2.783
COQ7 Coenzyme Q7 homolog, ubiquinone P97478 2.745
MYO1B Myosin IB P46735-2 2.635
SLC6A3 Solute carrier family 6 (neurotransmitter transporter),
member 3; NA+-dependent dopamine transporter
Q61327 2.497
SLC1A3 Solute carrier family 1 (glial high affinity glutamate
transporter), member 3; EAAT1, GLAST
P56564 2.370
STK26 Serine/threonine protein kinase 26 Q99JT2 2.325
WFS1 Wolfram syndrome 1 (wolframin) P56695 2.252
DOWN LIAS Lipoic acid synthetase Q99M04 −7.721
RPL28 Ribosomal protein L28 P41105 −6.233
CHERP Calcium homeostasis endoplasmic reticulum protein Q8CGZ0 −6.140
SERPINC1 Serpin peptidase inhibitor, clade C (antithrombin), member 1 P32261 −6.102
SERPINF2 Serpin peptidase inhibitor, clade F (alpha-2 antiplasmin,
pigment epithelium derived factor), member 2
Q61247 −4.441
KIAA1217 Sickle tail protein homolog A2AQ25−4 −4.407
ILF3 Interleukin enhancer binding factor 3, 90kDa Q9Z1X4 −4.204
TTR Transthyretin P07309 −4.120
GPX3 Glutathione peroxidase 3 P46412 −3.330
SERPINA3 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase,
antitrypsin), member 3
P07759 −3.188
TABLE 3 | Select top significantly altered analysis-ready molecules in the nucleus accumbens of mice receiving chronic ethanol treatment (relative to
control mice).
Direction of change Protein ID Protein name Accession number Log2 Fold change
UP CENPE Centromere protein E, 312kDa E9QKK1 3.07E+10
ITGA3 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) Q62470-3 5.67E+09
PDLIM4 PDZ and LIM domain 4 P70271 4.041
CPLX3 Complexin 3 Q8R1B5 2.899
HSPG2 Heparan sulfate proteoglycan 2 B1B0C7 2.867
H3F3A/H3F3B H3 histone, family 3A E0CZ27 2.737
DNMT1 DNA (cytosine-5-)-methyltransferase 1 J3QNW0 2.664
CBLN1 Cerebellin 1 precursor Q9R171 2.623
ITIH2 Inter-alpha-trypsin inhibitor heavy chain 2 Q61703 2.595
DOWN ADD1 Adducin 1 (alpha) E9Q1K3 −5.359
KCNQ3 Potassium channel, voltage gated KQT-like subfamily Q, member 3 Q8K3F6 −4.013
GDPD5 Glycerophosphodiester phosphodiesterase domain containing 5 Q640M6 −3.503
ELFN1 Extracellular leucine-rich repeat and fibronectin type III domain containing 1 Q8C8T7 −3.385
LAMP5 Lysosomal-associated membrane protein family, member 5 Q9D387 −3.080
MCTP1 Multiple C2 domains, transmembrane 1 E9PW38 −2.854
SMAD2 SMAD family member 2 Q62432−2 −2.801
KIRREL3 Kin of IRRE like 3 (Drosophila) G5E8B6 −2.746
APOB Apolipoprotein B E9Q1Y3 −2.568
OTOF Otoferlin D3YXV0 −2.531
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TABLE 4 | Select top significantly altered analysis-ready molecules in the nucleus accumbens of mice during acute withdrawal from chronic ethanol
(relative to mice receiving chronic ethanol).
Direction of change Protein ID Protein name Accession number Log2 Fold change
UP SLC35D3 Solute carrier family 35, member D3 Q8BGF8 7.436
ZDHHC17 zinc finger, DHHC-type containing 17 Q80TN5 6.049
WWP2 WW domain containing E3 ubiquitin protein ligase 2 Q9DBH0 5.844
ADD1 Adducin 1 (alpha) E9Q1K3 5.557
ELFN1 Extracellular leucine-rich repeat and fibronectin type III domain containing 1 Q8C8T7 5.47
FGFR3 Fibroblast growth factor receptor 3 Q61563 5.341
ABCB11 ATP-binding cassette, sub-family B (MDR/TAP), member 11 J3QNY6 4.457
GDPD5 Glycerophosphodiester phosphodiesterase domain containing 5 Q640M6 3.613
LAMP5 Lysosomal-associated membrane protein family, member 5 Q9D387 3.531
KCNQ3 Potassium channel, voltage gated KQT-like subfamily Q, member 3 Q8K3F6 3.201
DOWN CAMK2A Calcium/calmodulin-dependent protein kinase II alpha F8WIS9 −7.31E+10
PPM1L Protein phosphatase, Mg2+/Mn2+ dependent, 1L Q8BHN0 −3.48E+10
AVP Arginine vasopressin P35455 −5.26E+08
MOBP Myelin-associated oligodendrocyte basic protein Q9D2P8 −14.701
H3F3A/H3F3B H3 histone, family 3A E0CZ27 −11.249
CLDN11 Claudin 11 Q60771 −10.707
CPLX3 Complexin 3 Q8R1B5 −7.681
HIST1H1D Histone cluster 1, H1d P43277 −6.015
H2AFV H2A histone family, member V Q3THW5 −5.9
STX3 Syntaxin 3 Q64704-2 −4.468
The top significant upstream regulators predicted by IPA are
shown for the CPu (Figure 4A) and NAc (Figure 4B), with blue
indicating negative z-scores and red indicating positive z-scores.
Huntingtin (HTT) is a top predicted upstream regulator for
both groups (Figure 4C) in all but the NAc of E mice. HTT
appears to have reduced activity in all conditions, with a greater
predicted reduced activity in W mice (z-score = −1.842 for
CPu, −1.069 for NAc) than E mice (z-score = − 0.106
for CPu). The transcriptional repressor, Myc (Figures 4A,B),
however, shows far greater significance in the NAc than in
the CPu, predicted to be activated in E mice (z-score =
1.897) and inhibited during withdrawal (z-score = −2.673).
In contrast, Myc is predicted to be inhibited in the CPu of
E mice (z-score= − 0.447). Interestingly, L-dopa (Figure 4D)
is predicted to have increased activity in the CPu of W mice
(z-score = 3.664), and decreased activity in E mice (z-scores
CPu = − 2.236, NAc = −2.00), while dopamine is a predicted
upstream regulator in the CPu of W mice, (p = 2.48E-02)
though in an undeterminable direction. Also, based on changes
in B2M, BCL2L1, and SLC1A3 protein levels in the CPu of E
mice, L-glutamate (Figure 4A) is a predicted upstream regulator.
Similarly, mGluR3 is predicted to be an important upstream
regulator in the CPu during withdrawal based on changes in the
levels of GRM2, SLC1A2, and SLC1A3 (see Supplemental Data
sheet 3).
Protein Networks are Differentially
Affected by CIE and Withdrawal
The top protein networks associated with our differentially
expressed protein data set in E mice included cell morphology,
cellular development, cellular growth and proliferation (CPu)
and tissue development, cell death and survival, cardiovascular
system development and function (Table S1). The top networks
associated with the W mice data set included behavior, cell-
to-cell signaling and interaction, drug metabolism and biliary
hyperplasia, hepatic system development and function, liver
cholestasis (Table S2). Both groups showed high associations
with “cell-to-cell signaling and interaction” and “hereditary
disorder” (Huntington’s Disease), likely reflective of the tissue
and cell types analyzed. Illustrated in Figure 5 are two of
the top networks activated in the CPu for each condition.
These networks are overlaid with top canonical pathways based
on overlap p-values. Many of the top networks in the E
mice involved molecular and cellular functions, highlighted
by the apoptosis signaling and Huntington’s disease signaling
(encompassing many molecules necessary for normal neuronal
function) overlays in Figure 5A. The network illustrated in
Figure 5B reveals the interactions between behavioral signaling
and lipid metabolism with cell death and survival pathways,
with overlays highlighting proteins that are also involved in
glutamate receptor signaling, GPCR signaling, NFκB signaling
and schizophrenia.
The top implicated diseases and biological functions reflect
the activated networks for the two conditions, with greater
significance in overlap of molecules involved in molecular
and cellular functions (Figure 6C) and cell death and survival
(Figure 6D). In E mice (Figure 6), the biological functions of
cell morphology (CPu; Figure 6A) and mRNA translation and
cell attachment (NAc; Figure 6B) were the most significant,
with diseases such as schizophrenia ranking less significant
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FIGURE 4 | Predicted upstream regulators. The most significant predicted upstream regulators in the CPu (A) and NAc (B) are shown. Select pathways are
represented to illustrate the differential protein expressions that led to the status of upstream regulation prediction. Huntingtin (HTT) (C) is one of the most significantly
affected upstream regulators for both the CPu and the NAc, playing a major role in normal cellular maintenance. L-dopa (D) has a predicted decrease in activity during
CIE, and increase during withdrawal. (Color key: blue/green = decreased/down-regulated; orange/red = increased/up-regulated; “DA” = dopamine). Complete data
can be found in Supplemental Materials.
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FIGURE 5 | Top networks activated in the CPu during CIE and acute withdrawal. Illustrated here are select top network pathways for each condition in the
CPu. (A) The network encompassing neurological disease, skeletal and muscular disorders, and psychological disorders is shown for the CIE mice, and (B) the
network encompassing cell death and survival, behavior and lipid metabolism is shown for the withdrawal mice. Networks are overlaid with significantly affected
canonical pathways and diseases. (Color key: green = down-regulated, red = up-regulated, gray = molecule present in dataset but not significantly changed, white =
molecule important in pathway but not found in dataset; overlay colors are unique to each canonical pathway or disease). Complete data can be found in
Supplemental Materials.
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FIGURE 6 | The most significantly altered diseases and biological functions in the striatum of ethanol mice. Up-regulated (red), down-regulated (blue), and
indeterminable (gray) activation of diseases and biological functions in the caudate-putamen (A) and nucleus accumbens (B) are displayed according to overall
significance (p-value). Normalized signal intensities of proteins within the network heat maps shown in (C,D) are from the CPu samples (inclusive of serum proteins).
Complete data can be found in Supplemental Materials.
(CPu, p-value= 1.90E-03). However, more psychological
disorders and neurological diseases (Figure 7; heat maps of
pathway molecules in Figures 7C,D) were identified from
the differentially altered proteins in W mice. Among these,
schizophrenia (CPu; Figure 7A), and bipolar and mood
disorders (NAc; Figure 7B) were the top diseases identified,
along with biological functions of glutamate release and synaptic
vesicle exocytosis (Figures 7A,B).
DISCUSSION
In this report we undertook a label-free proteomic approach
to identify novel proteins associated with chronic ethanol
exposure and more importantly, withdrawal from that condition.
Unfortunately, a critical hallmark of alcohol addiction is the high
occurrence of relapse following a period of abstinence. Therefore,
it is of paramount importance that we elucidate novel proteins
and their associated molecular pathways (affected by CIE and
withdrawal) in order to adequately utilize pharmacological
treatment strategies to help individuals suffering from this
disease.
To model chronic alcohol use leading to dependence and
subsequent withdrawal we utilized the CIE protocol, which
has been demonstrated to accomplish these goals in previous
studies (Becker et al., 1997; Becker and Lopez, 2004). After
four cycles of CIE we were able to reproduce these previous
findings, generating appropriate BACs to result in alcohol
dependence and tolerance, validated by the increased alcohol
consumption and shorter time to recovery from LORR by
the mice that underwent the CIE procedure in comparison to
controls.
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FIGURE 7 | The most significantly altered diseases and biological functions in the striatum of withdrawal mice. Up-regulated (red), down-regulated (blue),
and indeterminable (gray) activation of diseases and biological functions in the caudate-putamen (A) and nucleus accumbens (B) are displayed according to overall
significance (p-value). Normalized signal intensities of proteins within the network heat maps shown in (C,D) are from the CPu samples (inclusive of serum proteins).
Complete data can be found in Supplemental Materials.
Label-free proteomic analysis using LC-MS/MS combined
with Ingenuity Pathway Analysis (IPA) revealed a plethora
of altered proteins and activated pathways and networks.
In order to focus on neuronal signaling pathways, we
excluded many proteins primarily found in blood serum.
We acknowledge that this may have resulted in reduced
recognition of immune signaling and lipid/cholesterol pathways,
and that validation and functional studies are warranted.
Indeed, when these molecules were included in the IPA analysis
(data not shown), we found increased significance of overlap
with molecules involved in lipid/cholesterol (RXR signaling)
pathways and acute phase response with molecules in our
datasets.
Neuroproteomic analysis of the mouse striatum under
conditions of CIE or acute withdrawal from CIE validated
many previously identified signaling changes found in chronic
ethanol and withdrawal treatments. For example, we found
increased PDYN in withdrawal (Osterndorff-Kahanek et al.,
2013), decreased CNR1 during chronic ethanol and increased
LTD during withdrawal (DePoy et al., 2013), increased DRD3
(Rothblat et al., 2001) and decreased CAMKII signaling during
withdrawal (Spiga et al., 2014). Additionally, top activated
diseases and biological functions support recent theories and
observations on the networks associated with alcohol withdrawal
symptoms. For instance, medium spiny neurons in the putamen
of animals after 4 weeks of CIE displayed increased neuronal
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excitability, and disruption of the inhibitory striatonigral circuit
led to more severe withdrawal symptoms (Cuzon Carlson et al.,
2011), reflecting the increases in synaptic transmission and
increased glutamatergic signaling revealed in our withdrawal
samples (see Figure 7A). Brain stress hormones also appear
to affect the depression and anxiety symptoms seen during
alcohol withdrawal (Meinhardt and Sommer, 2015), disease
states that were implicated in the NAc dataset of our
withdrawal samples (see Figure 7B). Also, anti-hypertensive
medications that target the α- and β-adrenergic receptors,
signaling pathways that were differentially expressed in our
datasets, have been shown to improve withdrawal symptoms both
clinically and in animals (Trzaskowska and Kostowski, 1983),
supporting theories that the effects of these medications may
be directly on neural circuitry and not simply through systemic
actions.
Overall, we found more dramatic changes in protein
levels of the CPu samples than we did with the NAc
samples. One of the most striking findings was the significant
increase in glutamate signaling in the CPu during ethanol
withdrawal. This supports previous data that show increased
glutamatergic neurotransmission during ethanol withdrawal
(Tsai et al., 1998; Chen et al., 2011; Abulseoud et al.,
2014). Increased excitatory signaling due to excess synaptic
glutamate during withdrawal is considered to be a major
contributing factor to alcohol withdrawal syndrome, thus
stimulating discovery and testing of compounds potentially
used to ease withdrawal symptoms (Bayard et al., 2004). For
example, compounds like ceftriaxone show promising results
(Rothstein et al., 2005; Rao et al., 2015), as it has been
shown to increase the expression of glutamate transporters
that remove excess synaptic glutamate. In support, our CPu
neuroproteomic results confirm this increased glutamatergic
signaling in the dorsal striatum, which may lead to dis-
inhibition of the thalamus through both the direct and indirect
pathways (Chen et al., 2011; Cuzon Carlson et al., 2011), as
well as alterations in synaptic plasticity (Zhou and Danbolt,
2013).
Interestingly, we found that L-dopa, a catecholamine
precursor, was identified as an increased upregulator in the CPu
of W mice. Dopamine signaling, however, is decreased during
withdrawal after chronic alcohol exposure (Berke and Hyman,
2000; Koob and Volkow, 2010; Karkhanis et al., 2015), though
alcohol’s effects on dopamine signaling are still somewhat
controversial (Didone et al., 2016). Additionally, dopamine
receptor and transporter upregulation has also been found
under similar conditions (Rothblat et al., 2001), which may
explain our findings. The involvement of the dopamine system
in withdrawal symptoms has also been under investigation, as
striatopallidal projections have been implicated in withdrawal
tremors (Deik et al., 2012; Spiga et al., 2014), which appears to
involve dopamine signaling. Dopamine signaling also seems
to be involved in other psychotic symptoms (hallucinations,
dementia) associated with AWS and schizophrenia (Rao et al.,
2012). Notably, we found a significant overlap of pathway
molecules associated with dementia in the NAc of our Wmice.
Oxidative stress is a well-known cellular response to
ethanol exposure (Tsai et al., 1998; Toth et al., 2010;
Pochareddy and Edenberg, 2012; Moon et al., 2014), and
local mitochondrial function has been shown to have an
impact on dendritic morphogenesis and synaptic plasticity (Li
et al., 2004). Many proteins involved in oxidative stress and
the mitochondrial electron transport chain were affected in
our chronic ethanol and acute withdrawal samples, although
mainly components of complex I were significantly increased
during withdrawal. The NADH dehydrogenase complex I has
been implicated in certain neuropsychiatric disorders, such
as bipolar disorder and major depressive disorder (Andreazza
et al., 2010; Mazereeuw et al., 2015), as its dysfunction
results in increased ROS leading to a multitude of adverse
consequences (Trivedi and Deth, 2014), including activation of
the NLRP3 inflammasome and lipid peroxidation. Incidentally,
several pathways involved in lipid/cholesterol metabolism and
inflammatory responses (LXR/RXR, FXR/RXR, acute phase
response) were differentially activated in the E and W
mice (details can be found in Supplemental Data sheets 2,
3). Alterations in plasma membrane lipid composition can
affect surface protein trafficking and function (Tobin et al.,
2014), such as glutamate transport by excitatory amino acid
transporters (EAAT’s) (Butchbach et al., 2004). Perhaps plasma
membrane composition and integrity play a greater role in
the functions of key receptors and transporters in the striatum
than was previously thought. Also, the inflammatory response
to alcohol and its withdrawal is receiving increasing attention,
as astrocytes and microglia have been shown to play a key
role in neuronal integrity and synaptic plasticity, both of which
are affected in AUD (Crews et al., 2013; Olmos and Lladó,
2014).
Though much of our data confirm established consequences
of chronic ethanol use and withdrawal, our results support the
need for increased research into the application and development
of therapeutics targeted toward mitochondrial dysfunction and
reduction of glutamate transmission (possibly through increased
glutamate transport). Additionally, utilization of substances
improving plasma membrane integrity may be another avenue
to consider when treating AWS. We hope that these proteomic
analyses will prove useful for others investigating the causes of
AWS and treatment methods to aid in recovery from AUD.
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